疗效和安全性-话题@MedSci

#疗效和安全性#

431篇内容 | 2623人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1720995, encodeId=65691e20995d2, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=JTO：Rova-T联合纳武单抗或伊匹单抗治疗广泛期小细胞肺癌的疗效和安全性, objectType=article, longId=207873, objectId=e3af20e873d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3af20e873d7, replyNumber=0, likeNumber=69, createdTime=2021-04-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3af20e873d7, moduleTitle=JTO：Rova-T联合纳武单抗或伊匹单抗治疗广泛期小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3af20e873d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721008, encodeId=8ba31e210085b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Exp Rheumatol：2期临床试验结果证实尼塔奇单抗对活动性强直性脊柱炎良好的疗效和安全性, objectType=article, longId=210766, objectId=f03d210e6684, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f03d210e6684, replyNumber=0, likeNumber=92, createdTime=2021-10-13, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f03d210e6684, moduleTitle=Clin Exp Rheumatol：2期临床试验结果证实尼塔奇单抗对活动性强直性脊柱炎良好的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f03d210e6684)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721051, encodeId=172d1e21051ee, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, objectType=article, longId=214063, objectId=7ac421406392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ac421406392, replyNumber=0, likeNumber=89, createdTime=2021-08-14, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ac421406392, moduleTitle=Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ac421406392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721092, encodeId=9d281e21092b1, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Ann Rheum Dis：替拉珠单抗治疗活动性银屑病关节炎的疗效和安全性——随机、双盲、安慰剂对照、多剂量、52周的IIb期研究结果, objectType=article, longId=218828, objectId=bead21882881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bead21882881, replyNumber=0, likeNumber=80, createdTime=2022-01-05, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bead21882881, moduleTitle=Ann Rheum Dis：替拉珠单抗治疗活动性银屑病关节炎的疗效和安全性——随机、双盲、安慰剂对照、多剂量、52周的IIb期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bead21882881)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721153, encodeId=49551e211534c, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估 , objectType=article, longId=293393, objectId=a91729339309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91729339309, replyNumber=0, likeNumber=83, createdTime=2022-06-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91729339309, moduleTitle=Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91729339309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721150, encodeId=6ac71e2115081, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性, objectType=article, longId=292745, objectId=425c292e45ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=425c292e45ea, replyNumber=0, likeNumber=81, createdTime=2022-01-19, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=425c292e45ea, moduleTitle=Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=425c292e45ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721093, encodeId=4f2c1e2109368, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：阿帕替尼联合卡瑞利珠单抗在既往治疗过的晚期胆管癌患者中的疗效和安全性, objectType=article, longId=218851, objectId=26532188515c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26532188515c, replyNumber=0, likeNumber=60, createdTime=2022-05-18, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26532188515c, moduleTitle=Front Oncol：阿帕替尼联合卡瑞利珠单抗在既往治疗过的晚期胆管癌患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26532188515c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721018, encodeId=d2991e21018a5, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, objectType=article, longId=211288, objectId=122f21128838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=122f21128838, replyNumber=0, likeNumber=66, createdTime=2021-10-21, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=122f21128838, moduleTitle=Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=122f21128838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721142, encodeId=51e91e2114258, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, objectType=article, longId=265037, objectId=970226503ec6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=970226503ec6, replyNumber=0, likeNumber=71, createdTime=2022-04-25, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=970226503ec6, moduleTitle=J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=970226503ec6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721147, encodeId=21931e211473b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, objectType=article, longId=291974, objectId=52c52919e488, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52c52919e488, replyNumber=0, likeNumber=77, createdTime=2022-07-09, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52c52919e488, moduleTitle=Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52c52919e488)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721122, encodeId=7ebe1e2112224, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle= Int J Cardiol：德国研究显示，与其他口服抗凝剂相比，艾多沙班在房颤患者中具有更好的疗效和安全性, objectType=article, longId=220909, objectId=1b9e220909e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b9e220909e9, replyNumber=0, likeNumber=80, createdTime=2022-04-20, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b9e220909e9, moduleTitle= Int J Cardiol：德国研究显示，与其他口服抗凝剂相比，艾多沙班在房颤患者中具有更好的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b9e220909e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721074, encodeId=cb511e210742e, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性, objectType=article, longId=216936, objectId=12a7216936f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12a7216936f0, replyNumber=0, likeNumber=69, createdTime=2022-05-26, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12a7216936f0, moduleTitle=BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12a7216936f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721108, encodeId=73141e211081a, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Diabetes Obes Metab:口服沙格列汀治疗日本2型糖尿病患者的疗效和安全性, objectType=article, longId=220124, objectId=2ab322012418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ab322012418, replyNumber=0, likeNumber=85, createdTime=2022-06-15, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ab322012418, moduleTitle=Diabetes Obes Metab:口服沙格列汀治疗日本2型糖尿病患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ab322012418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721134, encodeId=c4ab1e211340c, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, objectType=article, longId=221343, objectId=6363221343dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6363221343dc, replyNumber=0, likeNumber=84, createdTime=2022-07-18, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6363221343dc, moduleTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6363221343dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721112, encodeId=78de1e2111219, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：替莫唑胺联合阿帕替尼治疗复发性胶质母细胞瘤的疗效和安全性, objectType=article, longId=220476, objectId=41ac2204e60d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41ac2204e60d, replyNumber=0, likeNumber=61, createdTime=2022-06-16, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41ac2204e60d, moduleTitle=Front Oncol：替莫唑胺联合阿帕替尼治疗复发性胶质母细胞瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41ac2204e60d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721140, encodeId=a7a51e21140e6, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, objectType=article, longId=221519, objectId=836f22151965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=836f22151965, replyNumber=0, likeNumber=74, createdTime=2022-02-24, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=836f22151965, moduleTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=836f22151965)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721082, encodeId=29531e210821b, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性, objectType=article, longId=217767, objectId=989c21e7670d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=989c21e7670d, replyNumber=0, likeNumber=61, createdTime=2022-08-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989c21e7670d, moduleTitle=Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989c21e7670d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721034, encodeId=e4251e2103468, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, objectType=article, longId=213115, objectId=9d6a213115e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d6a213115e4, replyNumber=0, likeNumber=75, createdTime=2021-12-28, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d6a213115e4, moduleTitle=Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d6a213115e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721139, encodeId=582f1e21139ac, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, objectType=article, longId=221472, objectId=77c32214e24c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77c32214e24c, replyNumber=0, likeNumber=79, createdTime=2022-03-26, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77c32214e24c, moduleTitle=J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77c32214e24c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1721031, encodeId=bab81e21031b9, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, objectTitle=Cancers：放疗联合S-1治疗头颈部肿瘤的的疗效和安全性：来自Meta分析, objectType=article, longId=212730, objectId=dfbe212e30d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfbe212e30d5, replyNumber=0, likeNumber=88, createdTime=2021-11-17, rootId=0, userName=经常头晕, userId=16ef32982072, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfbe212e30d5, moduleTitle=Cancers：放疗联合S-1治疗头颈部肿瘤的的疗效和安全性：来自Meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfbe212e30d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性

2020-05-29

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

JTO：Rova-T联合纳武单抗或伊匹单抗治疗广泛期小细胞肺癌的疗效和安全性

2021-04-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Exp Rheumatol：2期临床试验结果证实尼塔奇单抗对活动性强直性脊柱炎良好的疗效和安全性

2021-10-13

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur J Cancer：帕博西尼、派姆单抗和来曲唑联合治疗HR+转移性乳腺癌的疗效和安全性

2021-08-14

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Ann Rheum Dis：替拉珠单抗治疗活动性银屑病关节炎的疗效和安全性——随机、双盲、安慰剂对照、多剂量、52周的IIb期研究结果

2022-01-05

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估

2022-06-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Cancer Immunol Immunother：免疫检查点抑制剂(ICIs)联合瑞戈非尼（regorafenib）治疗晚期或转移性微卫星稳定（MSS）结直肠癌的疗效和安全性

2022-01-19

hb2008ye (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：阿帕替尼联合卡瑞利珠单抗在既往治疗过的晚期胆管癌患者中的疗效和安全性

2022-05-18

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Lancet oncol：派姆单抗联合西妥昔单抗治疗复发性/转移性HNSCC的疗效和安全性

2021-10-21

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：T-DM1+帕妥珠单抗 vs 紫杉类+曲妥珠单抗+帕妥珠单抗治疗高危HER2+早期乳腺癌患者的疗效和安全性：III期临床研究KAITLIN

2022-04-25

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clin Cancer Res：Cabozantinib（卡博替尼）单药治疗难治性软组织肉瘤(STS)的疗效和安全性

2022-07-09

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Int J Cardiol：德国研究显示，与其他口服抗凝剂相比，艾多沙班在房颤患者中具有更好的疗效和安全性

2022-04-20

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

BJD:瑞莎珠单抗vs司库奇尤单抗在中度至重度斑块状银屑病患者中的疗效和安全性

2022-05-26

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Diabetes Obes Metab:口服沙格列汀治疗日本2型糖尿病患者的疗效和安全性

2022-06-15

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性

2022-07-18

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：替莫唑胺联合阿帕替尼治疗复发性胶质母细胞瘤的疗效和安全性

2022-06-16

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性

2022-02-24

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Cancers：帕妥珠单抗和曲妥珠单抗联合局部放疗治疗HER2阳性乳腺癌患者的疗效和安全性

2022-08-17

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Liver Cancer：卡博替尼（Cabozantinib）治疗不可手术切除肝细胞癌的疗效和安全性：真实世界研究结果

2021-12-28

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

J Clin Oncol：CHOP方案加用罗米地辛治疗复发/难治性外周T细胞淋巴瘤的疗效和安全性

2022-03-26

经常头晕 (审核中...)

前往app查看评论内容

#疗效和安全性#

Cancers：放疗联合S-1治疗头颈部肿瘤的的疗效和安全性：来自Meta分析

2021-11-17

科室
- - 订阅+
  - 更多科室
工具
服务